PMV Pharma Targets NDA Submission for rezatapopt in 2027
"The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027," said David Mack, President and Chief Executive Officer of PMV Pharma. "We are also encouraged by the publication of the PYNNACLE Phase 1 results in the New England Journal of Medicine, which underscores the scientific innovation behind rezatapopt and highlights its potential to address a significant unmet medical need. Patients with TP53 Y220C advanced solid tumors, including platinum resistant ovarian cancer, experience poor outcomes despite available therapies."
Trade with 70% Backtested Accuracy
Analyst Views on PMVP
About PMVP
About the author
PMV Pharmaceuticals Q1 Financial Report Analysis
- Financial Performance: PMV Pharmaceuticals reported a Q1 GAAP EPS of -$0.34, indicating ongoing challenges in profitability, although cash and cash equivalents remain at $93.5 million, down from $112.9 million as of December 31, 2025.
- Operating Cash Flow: For the quarter ended March 31, 2026, PMV's net cash used in operations was $19.7 million, an increase from $18.3 million in the same period of 2025, reflecting heightened pressure on operational expenditures.
- R&D Spending Changes: R&D expenses for Q1 were $15.3 million, down from $17.4 million in Q1 2025, primarily due to reduced costs associated with contractual research organizations, indicating a strategic shift in R&D spending.
- Decrease in Administrative Costs: PMV's general and administrative expenses were $3.7 million, down from $4.1 million in Q1 2025, mainly due to lower personnel expenses and a reduction in legal support costs, showcasing the company's efforts in cost management.
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: PMV Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.48, exceeding expectations by $0.06, indicating some resilience in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, a significant decline from $183.3 million in 2024, reflecting pressure on the company's financial management.
- Operational Cash Usage: The net cash used in operations for FY 2025 was $73.6 million, a 42.8% increase from $51.3 million in 2024, suggesting greater challenges in operational expenditures that could impact future liquidity.
- Widening Net Loss: The net loss for FY 2025 was $77.7 million, up 32.3% from $58.7 million in 2024, which may raise investor concerns about the company's ongoing profitability and affect market confidence.
PMV Pharmaceuticals Reveals New Interim Data on Rezatapopt Monotherapy from Ongoing PYNNACLE Phase 2 Trial for Various Solid Tumors with TP53 Y220C Mutation
Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.
Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.
Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).
Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.
PMV Pharmaceuticals' Small-Cap Cancer Drug Demonstrates Verified Efficacy Across 8 Tumor Types
Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.
Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
PMV Pharmaceuticals Q1 Financial Report Analysis
- Financial Performance: PMV Pharmaceuticals reported a Q1 GAAP EPS of -$0.34, indicating ongoing challenges in profitability, although cash and cash equivalents remain at $93.5 million, down from $112.9 million as of December 31, 2025.
- Operating Cash Flow: For the quarter ended March 31, 2026, PMV's net cash used in operations was $19.7 million, an increase from $18.3 million in the same period of 2025, reflecting heightened pressure on operational expenditures.
- R&D Spending Changes: R&D expenses for Q1 were $15.3 million, down from $17.4 million in Q1 2025, primarily due to reduced costs associated with contractual research organizations, indicating a strategic shift in R&D spending.
- Decrease in Administrative Costs: PMV's general and administrative expenses were $3.7 million, down from $4.1 million in Q1 2025, mainly due to lower personnel expenses and a reduction in legal support costs, showcasing the company's efforts in cost management.
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: PMV Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.48, exceeding expectations by $0.06, indicating some resilience in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, a significant decline from $183.3 million in 2024, reflecting pressure on the company's financial management.
- Operational Cash Usage: The net cash used in operations for FY 2025 was $73.6 million, a 42.8% increase from $51.3 million in 2024, suggesting greater challenges in operational expenditures that could impact future liquidity.
- Widening Net Loss: The net loss for FY 2025 was $77.7 million, up 32.3% from $58.7 million in 2024, which may raise investor concerns about the company's ongoing profitability and affect market confidence.
PMV Pharmaceuticals Reveals New Interim Data on Rezatapopt Monotherapy from Ongoing PYNNACLE Phase 2 Trial for Various Solid Tumors with TP53 Y220C Mutation
Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.
Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.
Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).
Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.
PMV Pharmaceuticals' Small-Cap Cancer Drug Demonstrates Verified Efficacy Across 8 Tumor Types
Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.
Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
